ADCendo ApS
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.adcendo.dk
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Phase 1
Recruiting
- Conditions
- Metastatic Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma
- Interventions
- Biological: Antibody-drug conjugate (ADC)
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Adcendo ApS
- Target Recruit Count
- 270
- Registration Number
- NCT06797999
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York City, New York, United States
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Adcendo ApS
- Target Recruit Count
- 66
- Registration Number
- NCT06597721
- Locations
- 🇺🇸
Yale University Cancer Center, New Haven, Connecticut, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇦🇺Scientia Clinical Research, Randwick, New South Wales, Australia
News
No news found